Differences in Medication Adherence, satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic regimens

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 285-290

  Sweileh, Waleed M ^a   Ihbesheh, Manal S ^a   Jarar, Ikhlas S ^a   Sawalha, Ansam F ^a   Abu Taha, Adham S ^a   Zyoud, Sa'ed H ^b   Morisky, Donald E ^c  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^b SCHOOL OF PHYSICS   (Malaysia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic regimens; Medication adherence; Schizophrenia; Treatment satisfaction

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; SYMPTOM;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTPATIENTS; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84855896191     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918755     Document Type: Article

References (35)

1. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26(1): 25-40.
2. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18(13): 877-93.
3. Byrne MK, Deane FP, Caputi P. Mental health clinicians' beliefs about medicines, attitudes, and expectations of improved medication adherence in patients. Eval Health Prof 2008; 31(4): 390-403.
4. Kim SW, Yoon JS, Choi SK. Survey of medication adherence in patients with schizophrenia--Korean ADHES data. Hum Psychopharmacol 2006; 21(8): 533-7.
5. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002; 28(3 Pt 1): 266-72.
6. Svestka J, Bitter I. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders. Neuro Endocrinol Lett 2007; 28(Suppl 1): 95-116.
7. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61(Suppl 8): 5-11; discussion 2-3.
8. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61(5): 382-6.
9. Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 21; 41(2): 349-55.
10. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51(2): 216-22.
11. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19(7): 619-26.
12. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159(1): 103-8.
13. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006; 1(1): 47-56.
14. Tibaldi G, Salvador-Carulla L, Garcia-Gutierrez JC. From treatment adherence to advanced shared decision making: new professional strategies and attitudes in mental health care. Curr Clin Pharmacol 2011; 6(2): 91-9.
15. Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, et al. Predictors for starting depot administration of risperidone in chronic users of antipsychotics. J Clin Psychopharmacol 2008; 28(6): 625-30.
16. Borras L, Mohr S, Brandt PY, Gillieron C, Eytan A, Huguelet P. Religious beliefs in schizophrenia: their relevance for adherence to treatment. Schizophr Bull 2007; 33(5): 1238-46.
17. Bussing A, Abu-Hassan WM, Matthiessen PF, Ostermann T. Spirituality, religiosity, and dealing with illness in Arabic and German patients. Saudi Med J 2007; 28(6): 933-42.
18. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003; 37(5): 625-30.
19. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials 2000; 21(5 Suppl): 188S-94S.
20. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10(5): 348-54.
21. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
22. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8 Suppl 1: S9-S24.
23. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 2009; 7: 36.
24. Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep 1962; 10(3): 799-812.
25. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 21: 97-9.
26. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale. The drift busters. Int J Methods Psychiatr Res 1993; 3: 221-24.
27. Ruggeri M, Koeter M, Schene A, Bonetto C, Vazquez-Barquero JL, Becker T, et al. Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. Schizophr Res 2005; 1; 75(1): 107-17.
28. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatr Res 2006; 15; 144(2-3): 177-89.
29. Meier J, Becker T, Patel A, Robson D, Schene A, Kikkert M, et al. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc 2010; 19(3): 251-9.
30. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63(10): 1079-87.
31. Gibson TB, Jing Y, Kim E, Bagalman E, Wang S, Whitehead R, et al. Cost-sharing effects on adherence and persistence for secondgeneration antipsychotics in commercially insured patients. Manag Care 2010; 19(8): 40-7.
32. Schulte PF, Bogers JP, Steenhoek A. [First generation versus second generation antipsychotics: little benefit in the real world]. Tijdschr Psychiatr 2010; 52(3): 181-90.
33. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; 25(9): 2197-206.
34. Gutierrez-Casares JR, Canas F, Rodriguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr 2010; 15(5): 327-37.
35. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatr Suppl 2009; 52: S20-8.